As one of the most promising tools for deep analyses of tumor characteristics, single-cell RNA sequencing (scRNA-seq) is well welcomed for the great advantages of analyzing tumor features at single cell levels (1). However, the substantial gap between clinical practice and basis research on scRNA-seq still could not be ignored. In recent years, cancer immunotherapies that targeted tumor-specific T cells have made tremendous progress for a large number of patients with different types of cancers. However, absolute differences among patients receiving immunotherapies force us to look for efficient biomarkers to identify patients that could benefit from immunotherapies. And limited targets substantially preclude patients from benefiting from immunotherapy. As central players in tumor microenvironment, tumor-infiltrating lymphocytes shape the properties of tumor, especially responses to immunotherapies (2). Indeed, many researches also attempted to explore the features of tumor-infiltrating T cells on single or few types of cancers (3,4). However, the results from few types of cancers make it difficult to identify the universal features of tumor-infiltrating T cells. Under this circumstance, a recent study conducted by Zheng et al. systematically depicted a comprehensive tumor infiltrating T cell landscape across many types of cancers, which completely paves the path for the clinical utility of scRNA-seq in cancer.

Zheng and his colleagues integrated 397,810 T cells of 316 patients with cancer derived from different sequencing platforms using the “minicluster” and batch effect correction algorithm Harmony. The integration analyses methods are very important for the precise exploring of scRNA-seq data, which could be considered in similar studies. Their analyses covered 21 different cancer types, which is the most comprehensive pan-cancer study on tumor-infiltrating T cells.

In this study, 17 CD8+ and 24 CD4+ metaclusters were identified and T cell types were defined by their expression signatures. Four CD8+ Tex cell populations were found to be the major potentially tumor-reactive T cells in the CD8+ compartment. The research team found that CD8+ T cells could develop from naïve T cells to either Temra or Tex cells. For T cell exhaustion states, the study initially inferred two different paths from naïve to Tex cells. The first path is from naïve cells to interleukin (IL)7R+ memory T cells to GZMK+ T cells to terminal Tex cells. The second path is from naïve cells to IL7R+ Tm cells to ZNF683+ Trm cells to terminal Tex cells. In addition to the two main paths, other complex cellular pathways to T cell exhaustion were also identified. Zheng et al. systematically studied the regulators related to CD8+ T cell exhaustion. In addition to the prominent regulators TOX, the team also identified many new transcription regulators such as SOX4 and FOXP3, which may be the target to regulate the exhaustion of T cells. The universal regulators across cancer types deserve further exploitation for novel targets of immunotherapy.

The study also analyzed the T cell distribution patterns among cancer types. Results showed that T cell compositions obviously varied across cancer types, which suggested the difference in response to immunotherapy. And precise therapeutic targets on these cells should consider the cancer types’ specificity. For microenvironment-shaping factors, the study found the tumor mutation burden and FAT1 somatic mutations could affect T cell compositions. And the TGF-β and interferons may also affect components of the potentially tumor-reactive T cells.
To explore the clinical significance of tumor-infiltrating T cells, research groups constructed immune classification by the composition of T cells. All patients could be divided into $\text{Tex}^{\text{lo}}\text{Trm}^{\text{hi}}$ and $\text{Tex}^{\text{hi}}\text{Trm}^{\text{lo}}$. And the immune types could efficiently predict the response to immunotherapy and prognosis. However, distributions in samples of cancer make the predictive value look limited. Larger-sample research on each type of cancer and systematical analyses similar to this study are necessary for the promotion of this immune type and implementation in clinical application. The inconsistent results between gastric cancer and other types of cancer also deserve further study.

This research provided the most comprehensive map of tumor-infiltrating T cells, which laid a solid foundation and constructed a valuable treasure house for immunotherapy of cancer patients. Many promising targets on T cells from this research will be warmly further studied in the future. The visionary design and fruitful outcomes will make this study a great scientific hallmark in cancer research.

**Acknowledgements**

None.

**Footnote**

*Conflicts of Interest:* The authors have no conflicts of interest to declare.

**References**

1. Papalexi E, Satija R. Single-cell RNA sequencing to explore immune cell heterogeneity. Nat Rev Immunol 2018;18:35-45.
2. Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 2020;20:651-68.
3. Zhang L, Yu X, Zheng L, et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature 2018;564:268-72.
4. Zheng C, Zheng L, Yoo JK, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell 2017;169:1342-56.e1316.
5. Zheng L, Qin S, Si W, et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science 2021;374:abe6474.

---

**Cite this article as:** Wang A, Bu Z. Pan-cancer tumor-infiltrating T cells: A great hallmark in cancer immunology research. Chin J Cancer Res 2022;34(2):115-116. doi: 10.21147/j.issn.1000-9604.2022.02.06